http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020202719-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a80cbaaeee718664126e579cf4e41c2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d6ddbc6a01b364b72bd01042fb5768b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0dbcc7f4b4d5333f54cf6c92b6eee7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15e1f93f8225a28f01368cfd5dd22240 |
| publicationDate | 2022-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2020202719-B2 |
| titleOfInvention | Administration of tasimelteon under fasted conditions |
| abstract | One embodiment of the invention provides a method for administering tasimelteon to a human npatient that comprises orally administering an effective dose of tasimelteon under fasted nconditions. Fasted conditions may comprise administering the tasimelteon without food, no nfood at least 1/2 hour prior to administration, no food at least 1 hour prior to administration, no nfood at least 1-1/2 hours prior to administration, no food at least 2 hours prior to administration, nno food at least 2-1/2 hours prior to administration, or no food at least 3 hours prior to nadministration. According to such embodiments, tasimelteon may be administered, for nexample, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the npatient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for nexample, Non-24 Disorder. |
| priorityDate | 2014-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.